Literature DB >> 20830944

Negotiating living with an arteriovenous fistula for hemodialysis.

Cleo J Richard1, Joan Engebretson.   

Abstract

The purpose of this study was to examine how clients with end stage renal disease on hemodialysis negotiate living with an arteriovenous fistula. A fistula is the preferred access for hemodialysis, and clients must continually monitor and protect their fistula. In this qualitative, ethnographic study, data were collected during fieldwork and semistructured interviews. Constructivism and a cultural negotiation model provided frameworks for the study. Fourteen clients were interviewed; interviews lasted 1.5 to 4 hours. Results revealed new insights into informants'perspectives and experiences with a vascular access. The overarching theme was vulnerability, and underlying themes were body awareness, dependency, mistrust, and stigma. The response to vulnerability was to be continually vigilant and assertive to protect the holistic self Stigma of the vascular access was an important issue for informants and evoked the greatest emotional responses.

Entities:  

Mesh:

Year:  2010        PMID: 20830944

Source DB:  PubMed          Journal:  Nephrol Nurs J        ISSN: 1526-744X            Impact factor:   0.959


  4 in total

1.  Qualitative Research in Nephrology: An Introduction to Methods and Critical Appraisal.

Authors:  Noa Amir; Hugh J McCarthy; Allison Tong
Journal:  Kidney360       Date:  2021-02-22

2.  Self-cannulation: enabling patients' independence.

Authors:  Deborah Brouwer
Journal:  NDT Plus       Date:  2011-12

3.  Improving vascular access outcomes: attributes of arteriovenous fistula cannulation success.

Authors:  Lori E Harwood; Barbara M Wilson; Abe Oudshoorn
Journal:  Clin Kidney J       Date:  2016-02-04

4.  Work of being an adult patient with chronic kidney disease: a systematic review of qualitative studies.

Authors:  Javier Roberti; Amanda Cummings; Michelle Myall; Jonathan Harvey; Kate Lippiett; Katherine Hunt; Federico Cicora; Juan Pedro Alonso; Carl R May
Journal:  BMJ Open       Date:  2018-09-04       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.